CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
DuraSealdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01601691
NCT01601691N/ACompleted

Protection of Rectum From High Radiation Doses

University of Oulu·interventional·Posted May 18, 2012·Updated Nov 14, 2014

In Brief

A clinical study evaluating DuraSeal for Prostate Cancer. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the usefulness of diluted DuraSeal product as a spacer between prostate and rectum in prostate cancer low dose brachytherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFinland

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 18, 2012
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2013
Study CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.1 years ago

Interventions

DuraSealdevice

Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate